MeiraGTx (MGTX) Projected to Post Quarterly Earnings on Thursday

MeiraGTx (NASDAQ:MGTX) is anticipated to announce its earnings results before the market opens on Thursday, March 13th. Analysts expect the company to announce earnings of ($0.48) per share and revenue of $1.50 million for the quarter.

MeiraGTx Trading Up 0.2 %

MeiraGTx stock opened at $6.10 on Wednesday. The firm’s 50-day moving average is $6.47 and its 200-day moving average is $5.76. The company has a debt-to-equity ratio of 0.86, a quick ratio of 2.34 and a current ratio of 2.34. MeiraGTx has a 1 year low of $3.85 and a 1 year high of $7.80. The company has a market cap of $476.73 million, a P/E ratio of -5.04, a PEG ratio of 0.37 and a beta of 1.23.

Analyst Ratings Changes

A number of research analysts have recently issued reports on MGTX shares. Royal Bank of Canada raised their price target on shares of MeiraGTx from $9.00 to $11.00 and gave the stock an “outperform” rating in a research report on Thursday, November 14th. Chardan Capital reaffirmed a “buy” rating and issued a $36.00 price objective on shares of MeiraGTx in a report on Monday, February 24th.

Insider Buying and Selling

In other MeiraGTx news, CFO Richard Giroux sold 24,000 shares of the firm’s stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $6.29, for a total transaction of $150,960.00. Following the transaction, the chief financial officer now owns 849,947 shares of the company’s stock, valued at approximately $5,346,166.63. This trade represents a 2.75 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Alexandria Forbes sold 35,839 shares of the firm’s stock in a transaction dated Tuesday, January 7th. The shares were sold at an average price of $6.47, for a total transaction of $231,878.33. Following the transaction, the chief executive officer now directly owns 1,395,102 shares in the company, valued at approximately $9,026,309.94. The trade was a 2.50 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 8.40% of the company’s stock.

MeiraGTx Company Profile

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia.